Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Zenas BioPharma, Inc. (ZBIO) had Normalized Income after Taxes of $-111.46M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$1.00M |
|
$-111.46M |
|
-- |
|
$1.00M |
|
$108.66M |
|
$-107.66M |
|
$-3.68M |
|
$-111.34M |
|
$-111.34M |
|
$-111.46M |
|
$-111.46M |
|
$-111.46M |
|
|
Normalized Income after Taxes |
$-111.46M |
$-107.66M |
|
$-107.66M |
|
63.11M |
|
63.11M |
|
$-1.77 |
|
$-1.77 |
|
| Balance Sheet Financials | |
$653.79M |
|
$0.02M |
|
$47.90M |
|
$701.69M |
|
$65.82M |
|
$388.75M |
|
$388.77M |
|
$454.59M |
|
$247.10M |
|
$247.10M |
|
$247.10M |
|
63.33M |
|
| Cash Flow Statement Financials | |
$-132.43M |
|
$-256.09M |
|
$475.54M |
|
$110.64M |
|
$196.58M |
|
$85.94M |
|
$17.81M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.93 |
|
-- |
|
-- |
|
0.61 |
|
1.57 |
|
100.00% |
|
-10765.90% |
|
-10765.90% |
|
-- |
|
-11134.20% |
|
-11145.60% |
|
$-132.44M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-45.11% |
|
-45.11% |
|
-15.88% |
|
-17.53% |
|
$3.90 |
|
$-2.10 |
|
$-2.10 |
|